"Prealbumin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tetrameric protein, molecular weight between 50,000 and 70,000, consisting of 4 equal chains, and migrating on electrophoresis in 3 fractions more mobile than serum albumin. Its concentration ranges from 7 to 33 per cent in the serum, but levels decrease in liver disease.
Descriptor ID |
D011228
|
MeSH Number(s) |
D12.776.034.841.450 D12.776.124.727.750
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Prealbumin".
Below are MeSH descriptors whose meaning is more specific than "Prealbumin".
This graph shows the total number of publications written about "Prealbumin" by people in this website by year, and whether "Prealbumin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 0 | 2 | 2 |
1998 | 0 | 1 | 1 |
2009 | 0 | 1 | 1 |
2012 | 1 | 0 | 1 |
2013 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
2015 | 2 | 0 | 2 |
2016 | 2 | 0 | 2 |
2017 | 1 | 2 | 3 |
2018 | 1 | 1 | 2 |
2019 | 1 | 0 | 1 |
2020 | 1 | 1 | 2 |
2021 | 0 | 1 | 1 |
2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prealbumin" by people in Profiles.
-
ATTR Epidemiology, Genetics, and Prognostic Factors. Methodist Debakey Cardiovasc J. 2022; 18(2):17-26.
-
Wild-Type Transthyretin Cardiac Amyloidosis Is Associated with Increased Antecedent Physical Activity. J Cardiovasc Transl Res. 2022 08; 15(4):689-691.
-
Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT. ESC Heart Fail. 2021 10; 8(5):3875-3884.
-
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021 02; 23(2):277-285.
-
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020 06; 34(3):357-370.
-
Positive family history decreases diagnosis time by over 200. Amyloid. 2019; 26(sup1):17.
-
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13; 379(11):1007-1016.
-
Nutrition and Inflammatory Biomarkers in Chronic Pancreatitis Patients. Nutr Clin Pract. 2019 Jun; 34(3):387-399.
-
Evaluation of Blood Biomarkers Associated with Risk of Malnutrition in Older Adults: A Systematic Review and Meta-Analysis. Nutrients. 2017 Aug 03; 9(8).
-
Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy. Ann Neurol. 2017 Jul; 82(1):44-56.